Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
株式のランク #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
株価
$150.78
最終同期: 2026-09-18
時価総額
$187.20B
変化(1日)
-0.08%
変化(1年)
32.15%
US
取引 Gilead Sciences, Inc. (GILD)

カテゴリー

Gilead Sciences, Inc.(GILD)の収益
Jun 2026 時点の収益 TTM: $30.46B
Gilead Sciences, Inc. の最新の財務報告によると、現在の収益 (TTM) は $30.46B です。2024 年には $28.75B の収益があり、これは 2023 年の $27.12B と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Gilead Sciences, Inc. の収益履歴(2000 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) $30.46B 3.44%
2025 $29.44B 2.40%
2024 $28.75B 6.04%
2023 $27.12B -0.60%
2022 $27.28B -0.09%
2021 $27.31B 10.60%
2020 $24.69B 9.98%
2019 $22.45B 1.46%
2018 $22.13B -15.24%
2017 $26.11B -14.09%
2016 $30.39B -6.89%
2015 $32.64B 31.13%
2014 $24.89B 122.19%
2013 $11.20B 15.46%
2012 $9.70B 15.70%
2011 $8.39B 5.48%
2010 $7.95B 13.38%
2009 $7.01B 31.40%
2008 $5.34B 26.14%
2007 $4.23B 39.78%
2006 $3.03B 49.19%
2005 $2.03B 53.13%
2004 $1.32B 52.63%
2003 $867.86M 85.92%
2002 $466.79M 99.68%
2001 $233.77M 19.54%
2000 $195.56M 0.00%
同業他社の収益
企業 収益 収益の差
$79.67B 161.58%
US
$97.93B 221.54%
US
$64.39B 111.41%
US
$77.52B 154.53%
CH
$66.40B 118.02%
US